{"id":"NCT03100825","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Long-term Safety Study of QVM149 in Japanese Patients With Asthma","officialTitle":"A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-28","primaryCompletion":"2018-09-18","completion":"2019-04-08","firstPosted":"2017-04-04","resultsPosted":"2020-04-07","lastUpdate":"2020-04-07"},"enrollment":96,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"QVM149","otherNames":["QVM149 150/50/160 Î¼g once daily, delivered as powder in hard capsules via Concept1 inhaler"]}],"arms":[{"label":"QVM149","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)","timeFrame":"Up to 52 Weeks","effectByArm":[{"arm":"QVM149","deltaMin":64,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":25,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":94},"commonTop":["Asthma","Nasopharyngitis","Dysphonia","Bronchitis","Pharyngitis"]}}